{"ticker": {"uuid": "e819594c-c2ec-407c-b30a-b300a02a9210", "symbol": "GKOS", "name": "Glaukos Corp", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/truist-adjusts-price-target-glaukos-132329485.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:23:29+00:00", "published_display": "16 Jul 2026 13:23", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Glaukos CFO's Stock Sale Really Mean for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdndLdm02MHpsV21FbnRHQzgwQmZJclR4cC1lTEd1T2o2NmdKM2RpMzZFUEVDR0JhdldMTXJkWnIweDZ1dk5IZElrSDhkWFhGQVZDWTNNRkFVUDZ3TjhRZGlObkg1dVMtclludTBWTEZoUXV4ektQclFiN3B0REJkN1BwMDNybGlMYTRsaEd6U0ZaOEJfRjNkVVZ1RGJENkVI?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T08:52:18+00:00", "published_display": "16 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock hits 52-week high at 156.7 USD", "summary": "Glaukos Corp's stock reached a 52-week high of $156.7 USD, reflecting a 58.41% increase over the past year. Despite its robust performance, the stock is considered overvalued by InvestingPro analysis, with a Fair Value estimated at $100.90, and the company remains unprofitable. R", "url": "https://www.investing.com/news/company-news/glaukos-corp-stock-hits-52week-high-at-1567-usd-93CH-4793884", "source_name": "Investing.com", "published_at": "2026-07-15T16:16:44", "published_display": "15 Jul 2026 16:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing", "summary": "An insider at Glaukos Corporation sold shares worth $1,550,000, as disclosed in a recent SEC filing. This transaction was reported on July 14, 2026. Glaukos is an ophthalmic pharmaceutical and medical technology company specializing in treatments for glaucoma, corneal disorders, ", "url": "https://www.marketscreener.com/news/glaukos-insider-sold-shares-worth-1-550-000-according-to-a-recent-sec-filing-ce7f5edcdf81f726", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T05:40:10", "published_display": "15 Jul 2026 05:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?", "summary": "Glaukos CFO Alex Thurman sold 10,000 shares of Glaukos (GKOS) stock worth $1.6 million on July 9, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite this insider sale, which represented 19% of his direct equity holdings, the article suggests it's not a bearish s", "url": "https://www.fool.com/coverage/filings/2026/07/14/glaukos-cfo-alex-thurman-sells-usd1-6-million-in-stock-what-should-investors-do-now/", "source_name": "The Motley Fool", "published_at": "2026-07-14T22:07:00", "published_display": "14 Jul 2026 22:07", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Glaukos SVP & CFO Alex Thurman sells $1.55m in common stock By Investing.com", "summary": "Alex R. Thurman, SVP and CFO of Glaukos Corp (NASDAQ: GKOS), executed stock option transactions on July 9, 2026, acquiring and subsequently selling 10,000 shares for a total of $1.55 million under a Rule 10b5-1 trading plan. The transactions occurred while Glaukos shares were tra", "url": "https://za.investing.com/news/stock-market-news/glaukos-svp--cfo-alex-thurman-sells-155m-in-common-stock-93CH-4367146", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T17:11:44", "published_display": "14 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) AGM 2026 Summary", "summary": "This article provides a summary of Glaukos's (GKOS) 2026 Annual General Meeting (AGM), held on May 28, 2026, which featured a virtual format. Key agenda items included the election of two Class II directors, advisory approval of executive compensation, and ratification of the ind", "url": "https://quartr.com/events/glaukos-gkos-agm-2026_ofdonTRk", "source_name": "Quartr", "published_at": "2026-07-11T04:10:23", "published_display": "11 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Stephens 26th Annual Investment Conference | NASH2024 Summary", "summary": "This summary from the Stephens 26th Annual Investment Conference highlights Glaukos's focus on innovative treatments for glaucoma and corneal diseases, moving beyond traditional methods. Key products include iDose for sustained glaucoma drug delivery, which is gaining market trac", "url": "https://quartr.com/events/glaukos-corporation-gkos-stephens-26th-annual-investment-conference-nash2024_ofdofmOs", "source_name": "Quartr", "published_at": "2026-07-10T23:09:35", "published_display": "10 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Glaukos Corp \u2013 XETR:6GJ", "summary": "This article provides financial information for Glaukos Corp (XETR:6GJ), specifically focusing on its forward price-to-sales ratio. It appears to be a page from a financial data platform like TradingView, showing market status and navigation options rather than a detailed analysi", "url": "https://www.tradingview.com/symbols/XETR-6GJ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T20:40:33", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise", "summary": "A recent Glaukos Corporation Form 144 filing indicates an intended sale of 10,000 common stock shares by Fidelity Brokerage Services LLC on July 9, 2026, valued at $1,550,000. This sale is associated with a stock option exercise on the same date. The filing also reports previous ", "url": "https://www.stocktitan.net/sec-filings/GKOS/144-glaukos-corp-sec-filing-30926803f745.html", "source_name": "Stock Titan", "published_at": "2026-07-10T16:39:08", "published_display": "10 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?", "summary": "Shares of Glaukos (GKOS) have surged over 45% since the end of May, outperforming the industry and S&P 500. This rally is primarily driven by investor confidence in its glaucoma therapy iDose TR, despite proposed Medicare restrictions, and the promising commercial launch of Epiox", "url": "https://finance.yahoo.com/markets/stocks/articles/gkos-stock-more-45-since-180400446.html", "source_name": "Market source", "published_at": "2026-07-09T16:09:35", "published_display": "09 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Insider Sold Shares Worth $1,500,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/glaukos-insider-sold-shares-worth-070633421.html", "source_name": "MT Newswires", "published_at": "2026-07-09T07:06:33+00:00", "published_display": "09 Jul 2026 07:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Glaukos\u2019 (GKOS) Demodex Bet Quietly Reshaping Its Post-Glaucoma Ophthalmic Strategy?", "summary": "Glaukos Corporation has fully enrolled 275 patients in a Phase 2 trial for GLK-321, a cream-based eyelid therapy for Demodex blepharitis, indicating a strategic expansion beyond glaucoma treatments. This move, alongside the momentum of iDose TR, suggests Glaukos is focusing on in", "url": "https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/is-glaukos-gkos-demodex-bet-quietly-reshaping-its-post-glauc", "source_name": "Simply Wall Street", "published_at": "2026-07-09T06:41:17", "published_display": "09 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Glaukos to Release Second Quarter 2026 Financial Results After Market Close on July 29", "summary": "Glaukos Corporation will release its second quarter 2026 financial results after market close on Monday, July 29, 2026. The company will also host a conference call and webcast to discuss the results, featuring a live question and answer session. Interested parties can access the", "url": "https://www.moomoo.com/news/post/72648010/press-release-glaukos-to-release-second-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-07-09T03:40:34", "published_display": "09 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) CFO executes pre-planned share sale and option exercise", "summary": "Glaukos Corp's Chief Financial Officer, Alex R. Thurman, conducted a pre-planned transaction on July 6, 2026, exercising options for 10,000 shares at $38.68 and simultaneously selling 10,000 shares at $150.00. This activity was executed under a Rule 10b5-1 trading plan establishe", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-de44cd3e2d0e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:40:21", "published_display": "09 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan", "summary": "Glaukos Corp's chief development officer, Tomas Navratil, sold 716 shares of company common stock at $139.06 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction, executed on July 1, 2026, represents a minor portion of his holdings, as he still directly owns ", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-a365a663339e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:40:21", "published_display": "09 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNX0o0dzJpMFNNUWx3UHRLcXN0OXpDYVU1VmFoTE02YkhYTW12M2VTaHczTzNOYlRqTnlCZGx1c3FrQ0l4Y1FhNEVlWGFDSnc3eTludHN1eGVCR0RzRUItYUdlMFQwZnVxd3JOdVpia29QdktDOElBZ0RXRnN6XzNkWFNpRUpJTmU0ZDlSWmhjdlNlWnRjUnNQLWY3d0FMbWs4NWFwU0huSnRGczZnOHpmOGs1Nmd5QmpSV21WYmRDQQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-08T22:03:00+00:00", "published_display": "08 Jul 2026 22:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29", "summary": "Glaukos Corporation (NYSE: GKOS) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results, with rep", "url": "https://www.businesswire.com/news/home/20260708528643/en/Glaukos-to-Release-Second-Quarter-2026-Financial-Results-after-Market-Close-on-July-29", "source_name": "Business Wire", "published_at": "2026-07-08T10:39:25", "published_display": "08 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp CFO Alex Thurman sells $1.5m in shares", "summary": "Alex R. Thurman, CFO of Glaukos Corp (NASDAQ:GKOS), sold 10,000 shares for $1.5 million at $150 per share, following an option exercise for the same number of shares at $38.68. The transactions were executed", "url": "https://www.investing.com/news/insider-trading-news/glaukos-corp-cfo-alex-thurman-sells-15m-in-shares-93CH-4782916", "source_name": "Investing.com", "published_at": "2026-07-08T09:15:00", "published_display": "08 Jul 2026 09:15", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos sets July 29 call for Q2 results after market close", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOX3I4NDlsTTFpX2VzMzZ4aVVzcmZrenNSd1JTSGNUX0tCczBzT0otRmstUl95emtuWTg5Z3RVS0dUMjE4dXM5b2xwNnlSNTlPZFFKWkFNM1JnUzJlWldoLWhTM05FU05aUXNVRzkxVlN4QUtuajZnbzMzT0VlNnAzWS1lSlpJZk9oXy1Zajhyb0MtY213clVRQVJTWko3UGFSM2F3ZEVFdDNvTWNlUFpQeUt1TWM1NGdF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Glaukos Corporation (GKOS) Affects Rotational Strategy Timing", "summary": "Quantitative analysis indicates strong sentiment for Glaukos Corporation (GKOS) across all time horizons, supporting an overweight bias. The article provides three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, a", "url": "https://news.stocktradersdaily.com/news_release/78/How_Glaukos_Corporation_GKOS_Affects_Rotational_Strategy_Timing_070726054202_1783460522.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T17:42:00", "published_display": "07 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock and its role in eye disease treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQLUJqWjBoeVdWN0ZuWVJPUWZ2TmxxbENsY0NtNElpOWpsYTdxLThRdHRndkU1dnQ4a256eDI3U1Q2VTBQc3pCc0RtellFS050OHpobzA0N2c3ZF9NeXdDbFprZ0lFU0Fuck12VkZVTHh2cDVwbVBhZEdjcWszZDRkZS1RR3lqZkJlRkVoWjlBaUpxVXlaZnloOU8tWGZVUVlLc1E4eVUtTEU1SkFqb3pBSm9xSlVsUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T15:20:20+00:00", "published_display": "07 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares", "summary": "Glaukos Corp. (NYSE: GKOS) has filed a Form 144, indicating a proposed sale of 10,000 shares of common stock stemming from a Stock Option Exercise. The filing lists Fidelity Brokerage Services LLC as the broker/dealer and cites July 6, 2026, as the securities-to-be-sold date, wit", "url": "https://www.stocktitan.net/sec-filings/GKOS/144-glaukos-corp-sec-filing-cdfdff5bcb82.html", "source_name": "Stock Titan", "published_at": "2026-07-06T15:40:36", "published_display": "06 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos stock rating reiterated at Outperform by William Blair", "summary": "William Blair has reiterated an Outperform rating on Glaukos Corporation (NYSE:GKOS) stock, which is trading near its 52-week high and is up 31% year-to-date despite recent losses. The reiteration comes as the company navigates a proposed local coverage determination (LCD) for it", "url": "https://www.investing.com/news/analyst-ratings/glaukos-stock-rating-reiterated-at-outperform-by-william-blair-93CH-4776090", "source_name": "Investing.com", "published_at": "2026-07-06T11:43:07", "published_display": "06 Jul 2026 11:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Gains Fresh Attention As Trial Progress Keeps Its Valuation Story Alive", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GKOS Jumps As Glaukos Wins Bullish Targets And Trial Milestone", "summary": "Glaukos Corporation (GKOS) stock surged by 7.84% following promising trial results for its glaucoma treatment, Epioxa, which also led to increased price targets from Citi and Needham. Analysts maintain an average \"Buy\" rating with a mean price target of $157.50, driven by the com", "url": "https://stockstotrade.com/news/glaukoscorporation-gkos-news-2026_07_04-2/", "source_name": "StocksToTrade", "published_at": "2026-07-04T15:09:21", "published_display": "04 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Proxy filing Summary", "summary": "Glaukos (GKOS) has scheduled its Annual Meeting for May 28, 2026, where shareholders will vote on director elections, executive compensation, and auditor ratification. The company reported a 32% net sales growth in 2025, reaching $507M, with major product launches like iDose TR a", "url": "https://quartr.com/events/glaukos-gkos-proxy-filing_ofdonT36", "source_name": "Quartr", "published_at": "2026-07-03T15:39:25", "published_display": "03 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWnBMYmhNSEo0aXdhWkVBSXBVYVRzUlQ2LXhFdWtSWkZKdUVMMk50cC1Fc0dWakc4M3BQbFB1WUVtX3hkWEhjc3dkLWdzYURmcTYwd0tNNHI2TUZ5ZzBRYzZ6bW5GWTRfMDVVd254VkJ6N2tEdDExRG9RbTBucXM1U3lmWWdneHYxa3JQWUZQeDdfemxjWGZoVUxxRV9aZkxMQWd5c2lqTzB0OUZwaHJGN0Z2dFJxYlluMHZJ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T21:24:00+00:00", "published_display": "02 Jul 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos stock hits 52-week high at 148.12 USD", "summary": "Glaukos (GKOS) stock has reached a new 52-week high of $148.12, reflecting a 40.91% increase in value over the past year and a nearly 22% year-to-date return, despite an InvestingPro analysis suggesting it may be overvalued. The company's revenue grew 36% in Q1 2026, and it recen", "url": "https://www.investing.com/news/company-news/glaukos-stock-hits-52week-high-at-14812-usd-93CH-4774011", "source_name": "Investing.com", "published_at": "2026-07-02T20:12:21", "published_display": "02 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 GLAUKOS Corp For: 1 July By Investing.com", "summary": "This article reports on the filing of Form 144 for GLAUKOS Corp, dated July 1st. It provides various financial market data and news headlines but no further details about the Form 144 itself. The content is primarily a placeholder announcement from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-144-glaukos-corp-for-1-july-93CH-4716682", "source_name": "Investing.com Canada", "published_at": "2026-07-01T16:40:06", "published_display": "01 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GKOS (GKOS) insider sells 3,630 shares total across April and June 2026", "summary": "A recent Form 144 filing indicates that Glaukos Corp (GKOS) insider Tomas Navratil sold a total of 3,630 shares across two transactions in April and June 2026, generating over $447,000. Additionally, Navratil had 716 shares vest on March 24, 2025, from restricted stock. These dis", "url": "https://www.stocktitan.net/sec-filings/GKOS/144-glaukos-corp-sec-filing-59558174726b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T16:40:06", "published_display": "01 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares", "summary": "Glaukos Corp's Chief Development Officer, Tomas Navratil, reported a tax-related share disposition. On June 25, 2026, 483 common shares were withheld by the company at $142.57 each to cover tax obligations from vested restricted stock units. Following this, Navratil directly hold", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-5c9426d606b7.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:36", "published_display": "30 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Glaukos Corp For: 29 June By Investing.com", "summary": "This article reports on a Form 4 filing for Glaukos Corp (GKOS) dated June 29. It notes a slight downturn in Glaukos Corp's stock and provides a financial markets overview. The piece also includes various market indices, commodity prices, and trending stock data.", "url": "https://ng.investing.com/news/stock-market-news/form-4-glaukos-corp-for-29-june-93CH-2579053", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T12:39:35", "published_display": "30 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Glaukos Corporation \u2013 NYSE:GKOS", "summary": "This page from TradingView provides financial information for Glaukos Corporation (NYSE: GKOS), specifically focusing on its forward price-to-sales ratio. It indicates that the company is listed on the New York Stock Exchange and presents various financial and community-related s", "url": "https://www.tradingview.com/symbols/NYSE-GKOS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:10:08", "published_display": "30 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding", "summary": "Glaukos Corp's CEO, Thomas William Burns, reported updated holdings of the company's common stock, primarily held through various family and charitable trusts. The update also indicated a disposition of 4,059 directly held shares at $142.57 each to cover tax obligations related t", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-15f7c7fef90d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T22:09:50", "published_display": "29 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Markets Slide this week \u2014 One Stock to Consider: Glaukos Corporation (NYSE: GKOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVmFKTTdKNEZLVzYxWTFrSzlWYm1rUmd5WUZQc3NPRkpsZTFtcU9hb295aGljNUhJZENRb3Z2WWZ2bG82elhla0pQN0VHaU1yekVQaXc0UUs2RVpIRVh5Z0lZRG95dl9hZ2VqTmJNbHhRbDBKclZfX19RWFhqbzVhRndBdGpRS1JBQ3dRMW82dENZWlZ0ZHFJWDZUUjBVMmpvZERxeU0tbDluS1FaUEE?oc=5", "source_name": "Kalkine", "published_at": "2026-06-26T12:43:00+00:00", "published_display": "26 Jun 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp Actuals & Estimates (NYSE:GKOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOZXFudWQ5Z3dWaG45dkE0UVZBdWtJQ1JFYkNCQm9rdFlnbEVCZzVqQUZNcWx6X0x1NUhNcUhDWjhBV0w3UXVLaEFQTW5JMFZQNXRlWmctSHFxaWpqUTVLbGtFdFNSUlNYUG5zZ1J2RmdsazNGVTZ5cGo1bEJtTDJwakRuMA?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T18:17:31+00:00", "published_display": "25 Jun 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeTVUSzkyYW44cUwzNGtLbWNnX2RCS0dOd3JyVENLdC0yMWU0NndiRHhCVUVzSERtMUVzemRybEpfTWlzVUpuSWhfYlEzSnhTLV9YYlpsSFN5RUpHd0o5aVJZMG5QcFJwLUJqdGxleVhLYzhJd3FlNkJJZHN5VmE2eXRQWFc2R2dKR19GYlBaTDlrTThVd1oxYjRSa3JUWTBnZ2VwS1RTYUxjQzlOMnVoOU1tbENPLXBsYWVOV29CQlRyc1hfenJEUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPLW1sTzJKZ2dHbUVkemZiRVNERm1pdGdpSTVDLWFPdHFJbWR0Yko0eTdmUnRHUVhzV3FTUF9jTVFKZGdfZ2VxcVVTdHhTNlhMZXlXNmdhUVJBS09vXzNWMFVTNE8taEVaZ0lXUC1tN3RTNlgzMUdRUkxScXdwbm9yNDd5SlpLbVoycTdWa3o4UXF5WW5iRHBvQVhnQzM3WmRI?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQLS1Ebm1sS1BaU3F3d0FQZjJ3TnkxWXlxejluSzUwUlFrdElZUFZrNFdsU09NT3Ayc0s4ejVUOUVsS2xLMkhzZVVyaE5oMnlERHhaMGllWkRXWWFOQlc5Z1RKVXprSklwSFEwbEYxRU1KanM2dFRnamtURFl1RFVTMFRlMXYzZEFOZmJRSUJpeFcycHV2cEpYenk2MA?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) director Leana Wen granted RSUs and options in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTkFhbVo1YTVYNGxTZHh2aUF3ZW1CRnFaM1lRYXRaYjYxbFVrWVhQcFVRZlYwR0RROGd1SEJiVEhVVDh1cTdHbkcxSmpwd0pBUjFsOTh4N3cyMkxRQ0ZaeFJPUVhROVZodnp3Z0hVb0l6dE5WSko1WEVwckt3bkhaU3lhdmVfSFV3anlHcFVWSDk5NlpLV2RDcDFFUnBKNkJpUGk5REtRX1Z0QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock (US3773221029): shares active on NYSE as market watches next catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOVlFfV0tKcmRncGR6QTNSOWo0cDREZXFMTGZSZG4xTmQwWWlKel9JT284c2RvdUsya194cGNQN1labUNpZjQ3c0VyWUpXWmtmUFNsYkVEdTlHd1A4cHRJTExfU0Nja2lJLXJORFQtN1FFN24yNXdBcFlkYW5sY19aWTVENG9FY1E4Q3dWVmhqZFRRcEF4V3lSSmwyZjRFdGVJZE8xUWhIWE5KN0RoeXUxR2tpaDQ1bndYZEEwcHA4TWlkMVdHbFlKYmVn?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQNlFxNmtMeGRBMEtnbHRyblhfbTJtdlpNa3NpOWhLemNfanZKdHFjN0gzRTRBOXIzb1hJVUVndGlpazNveVJMYk5jYlc4aWpXRl84bU5nT0ZCXzJlNm1SbGxPQWRyeXZOanhMTVp2N2lQQmVRUTJMTk16eEpJakJEYjRleW1RTUFjWHpuQkF0Y2xrMXlZZUxqcDJVRV9jY1BzN2J3RVE3bWt5eDRsNzJjYXJsRWN2WlFlc285TTVoZ3B0Z2p2T01Hb2pKZldmWW9yZG5BYlR0MHJ4R0ZoMkZUOFBLTjJ6S1lRWW5uQ2FYYmM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings Signal Promising Upside in the Medical Device Arena", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxORG1xRk5kREwwRERWeTZjY1ZweVFVQWVvcVdFdEVZV1YyNHJxNE5FeHBkWUhUVjlFN0VuWFYxWVp5RTkzWnl6VFBOZmQ1MXEwRVdUbnoxb2xIX3N5bjg2czhobExmY0xBRGNzMkpVR090dFgwVE80eTVxOUl0ek1ON3hyZVhMTEw0cjdlWjlUcFpUbUZWNE8xUk5PTnZVU3h0MWJTcGtUOGtTRkR0dnQ4RmVzWEdPcmVyLVFTcWtpWUVFTFVtZXE1QkYxQTBGVlZjcEswNUgzMkR0T3lxUGxmNTUxamcyTlVRbUx4NGc0aVhhMmM?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQY2lQTTJlZjJsV3FMb3dteXMySUZmOXVJY01ZRXE0WFVueklvVFRsZlZ3bXFrVl9EQmpxYzFHWFB0a2NnQ2pjdlUwM2k1RjhoS0FZT3BlMWlqVUNvUTNnQjMzcjBzSEZxVTBGclFiSlhJN05vTWFqN2JNZUxjWDlTZ3BSbEkyVlh0Sy1HdUFUNVBFcEhJcmVjRmRiajFxcmxHR1EtTE91dm4yeXdlUkhNSTkyNDdkNWlWTjI0dXZXOW9PNXBE0gHKAUFVX3lxTE1LWkZEUWRjd1pHMjBueFpvTV9vbEdmSEdDb1ZPY2N4cjlSdXV6OGFOT1Y5T3VfbDBoWEhMbzNHdjVJdzRwQjgwMEd3cnp2VmdZb0pyTHBQWUViV2xSRVRhQWFqdDBoSmNIUk9tOGl3UnpPY1dzcS1QclBkbGUwQlhnMVY5cElwV2kwdEtxQ2plOXBFM1gxQkNRQlZwVTFlQ3pwNzZ3OWRYRGVuZDlCbUZtMzdEdWJBVElqT1hzQzBhSk1hRlpuYnUxZkE?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Q1 Loss Of US$0.34 EPS Reinforces Bearish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOY1Uyd0h6eTFDUC1HZ0YxSmNicDJ0d3h5SElCSW4ySlJXVkZFeEFxZHNrelFKNmpVYlA0VVhfOXZTZ281MHRobkhwZXVDcUNob1R5TlZ6UlNHMVlkdmFtTXhDMy1JSTFFM1NQRVlWeVVlbkdyZFFRU2JBaWJmLTRHUXIxd0ZiTTY1Q2xzaVhOakhTSFpLZFg3Q3BnMVVsVnE4?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Rule 144: Fidelity lists 10,000\u2011share resale, insider trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNMm9naDFTcG9fWEhuYjVlQmZzQUhxd2NCaENRM2xPMUs2c3VEUzJHNHV4bGRuSUZBakM1bDJxVldQYzlOYmFVM2loeFEwbDZDdzNpd1ZwS1Z4QzZpaW9oREZQZ2N5SHQwekF3NHdRaS0wYTdxaWRBRWh4NWc1NUZWOVQ3aWRGNXR2RlcwNy1QZDJ6Mjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNQ21JZjRqRGlnTFAtM1pMSFdRWkM4RzE0Q1MtdzhEbjNvSEQ0angzYlJYWnUyUEQ4U1FkN2VRaXhYSEwtLUdOSDBtczNPUlVyR1hQNHR2VHMtYlF5UnBzdHUwZnVLSnBoTGN0MnpkekVEWjB3S3kxNmV6eGRQR2QzaXh4dG1BU2w0aDNoYTk1R1dlZ0tSa3JDcnA1d0c?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/truist-adjusts-price-target-glaukos-132329485.html", "source_name": "MT Newswires", "published_at": "2026-07-16T13:23:29+00:00", "published_display": "16 Jul 2026 13:23", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Glaukos CFO's Stock Sale Really Mean for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdndLdm02MHpsV21FbnRHQzgwQmZJclR4cC1lTEd1T2o2NmdKM2RpMzZFUEVDR0JhdldMTXJkWnIweDZ1dk5IZElrSDhkWFhGQVZDWTNNRkFVUDZ3TjhRZGlObkg1dVMtclludTBWTEZoUXV4ektQclFiN3B0REJkN1BwMDNybGlMYTRsaEd6U0ZaOEJfRjNkVVZ1RGJENkVI?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T08:52:18+00:00", "published_display": "16 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock hits 52-week high at 156.7 USD", "summary": "Glaukos Corp's stock reached a 52-week high of $156.7 USD, reflecting a 58.41% increase over the past year. Despite its robust performance, the stock is considered overvalued by InvestingPro analysis, with a Fair Value estimated at $100.90, and the company remains unprofitable. R", "url": "https://www.investing.com/news/company-news/glaukos-corp-stock-hits-52week-high-at-1567-usd-93CH-4793884", "source_name": "Investing.com", "published_at": "2026-07-15T16:16:44", "published_display": "15 Jul 2026 16:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing", "summary": "An insider at Glaukos Corporation sold shares worth $1,550,000, as disclosed in a recent SEC filing. This transaction was reported on July 14, 2026. Glaukos is an ophthalmic pharmaceutical and medical technology company specializing in treatments for glaucoma, corneal disorders, ", "url": "https://www.marketscreener.com/news/glaukos-insider-sold-shares-worth-1-550-000-according-to-a-recent-sec-filing-ce7f5edcdf81f726", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T05:40:10", "published_display": "15 Jul 2026 05:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?", "summary": "Glaukos CFO Alex Thurman sold 10,000 shares of Glaukos (GKOS) stock worth $1.6 million on July 9, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite this insider sale, which represented 19% of his direct equity holdings, the article suggests it's not a bearish s", "url": "https://www.fool.com/coverage/filings/2026/07/14/glaukos-cfo-alex-thurman-sells-usd1-6-million-in-stock-what-should-investors-do-now/", "source_name": "The Motley Fool", "published_at": "2026-07-14T22:07:00", "published_display": "14 Jul 2026 22:07", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos SVP & CFO Alex Thurman sells $1.55m in common stock By Investing.com", "summary": "Alex R. Thurman, SVP and CFO of Glaukos Corp (NASDAQ: GKOS), executed stock option transactions on July 9, 2026, acquiring and subsequently selling 10,000 shares for a total of $1.55 million under a Rule 10b5-1 trading plan. The transactions occurred while Glaukos shares were tra", "url": "https://za.investing.com/news/stock-market-news/glaukos-svp--cfo-alex-thurman-sells-155m-in-common-stock-93CH-4367146", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T17:11:44", "published_display": "14 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) AGM 2026 Summary", "summary": "This article provides a summary of Glaukos's (GKOS) 2026 Annual General Meeting (AGM), held on May 28, 2026, which featured a virtual format. Key agenda items included the election of two Class II directors, advisory approval of executive compensation, and ratification of the ind", "url": "https://quartr.com/events/glaukos-gkos-agm-2026_ofdonTRk", "source_name": "Quartr", "published_at": "2026-07-11T04:10:23", "published_display": "11 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Stephens 26th Annual Investment Conference | NASH2024 Summary", "summary": "This summary from the Stephens 26th Annual Investment Conference highlights Glaukos's focus on innovative treatments for glaucoma and corneal diseases, moving beyond traditional methods. Key products include iDose for sustained glaucoma drug delivery, which is gaining market trac", "url": "https://quartr.com/events/glaukos-corporation-gkos-stephens-26th-annual-investment-conference-nash2024_ofdofmOs", "source_name": "Quartr", "published_at": "2026-07-10T23:09:35", "published_display": "10 Jul 2026 23:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Glaukos Corp \u2013 XETR:6GJ", "summary": "This article provides financial information for Glaukos Corp (XETR:6GJ), specifically focusing on its forward price-to-sales ratio. It appears to be a page from a financial data platform like TradingView, showing market status and navigation options rather than a detailed analysi", "url": "https://www.tradingview.com/symbols/XETR-6GJ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T20:40:33", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise", "summary": "A recent Glaukos Corporation Form 144 filing indicates an intended sale of 10,000 common stock shares by Fidelity Brokerage Services LLC on July 9, 2026, valued at $1,550,000. This sale is associated with a stock option exercise on the same date. The filing also reports previous ", "url": "https://www.stocktitan.net/sec-filings/GKOS/144-glaukos-corp-sec-filing-30926803f745.html", "source_name": "Stock Titan", "published_at": "2026-07-10T16:39:08", "published_display": "10 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?", "summary": "Shares of Glaukos (GKOS) have surged over 45% since the end of May, outperforming the industry and S&P 500. This rally is primarily driven by investor confidence in its glaucoma therapy iDose TR, despite proposed Medicare restrictions, and the promising commercial launch of Epiox", "url": "https://finance.yahoo.com/markets/stocks/articles/gkos-stock-more-45-since-180400446.html", "source_name": "Market source", "published_at": "2026-07-09T16:09:35", "published_display": "09 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Insider Sold Shares Worth $1,500,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/glaukos-insider-sold-shares-worth-070633421.html", "source_name": "MT Newswires", "published_at": "2026-07-09T07:06:33+00:00", "published_display": "09 Jul 2026 07:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Glaukos\u2019 (GKOS) Demodex Bet Quietly Reshaping Its Post-Glaucoma Ophthalmic Strategy?", "summary": "Glaukos Corporation has fully enrolled 275 patients in a Phase 2 trial for GLK-321, a cream-based eyelid therapy for Demodex blepharitis, indicating a strategic expansion beyond glaucoma treatments. This move, alongside the momentum of iDose TR, suggests Glaukos is focusing on in", "url": "https://simplywall.st/stocks/us/healthcare/nyse-gkos/glaukos/news/is-glaukos-gkos-demodex-bet-quietly-reshaping-its-post-glauc", "source_name": "Simply Wall Street", "published_at": "2026-07-09T06:41:17", "published_display": "09 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Glaukos to Release Second Quarter 2026 Financial Results After Market Close on July 29", "summary": "Glaukos Corporation will release its second quarter 2026 financial results after market close on Monday, July 29, 2026. The company will also host a conference call and webcast to discuss the results, featuring a live question and answer session. Interested parties can access the", "url": "https://www.moomoo.com/news/post/72648010/press-release-glaukos-to-release-second-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-07-09T03:40:34", "published_display": "09 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) CFO executes pre-planned share sale and option exercise", "summary": "Glaukos Corp's Chief Financial Officer, Alex R. Thurman, conducted a pre-planned transaction on July 6, 2026, exercising options for 10,000 shares at $38.68 and simultaneously selling 10,000 shares at $150.00. This activity was executed under a Rule 10b5-1 trading plan establishe", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-de44cd3e2d0e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:40:21", "published_display": "09 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan", "summary": "Glaukos Corp's chief development officer, Tomas Navratil, sold 716 shares of company common stock at $139.06 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction, executed on July 1, 2026, represents a minor portion of his holdings, as he still directly owns ", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-a365a663339e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:40:21", "published_display": "09 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNX0o0dzJpMFNNUWx3UHRLcXN0OXpDYVU1VmFoTE02YkhYTW12M2VTaHczTzNOYlRqTnlCZGx1c3FrQ0l4Y1FhNEVlWGFDSnc3eTludHN1eGVCR0RzRUItYUdlMFQwZnVxd3JOdVpia29QdktDOElBZ0RXRnN6XzNkWFNpRUpJTmU0ZDlSWmhjdlNlWnRjUnNQLWY3d0FMbWs4NWFwU0huSnRGczZnOHpmOGs1Nmd5QmpSV21WYmRDQQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-08T22:03:00+00:00", "published_display": "08 Jul 2026 22:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29", "summary": "Glaukos Corporation (NYSE: GKOS) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results, with rep", "url": "https://www.businesswire.com/news/home/20260708528643/en/Glaukos-to-Release-Second-Quarter-2026-Financial-Results-after-Market-Close-on-July-29", "source_name": "Business Wire", "published_at": "2026-07-08T10:39:25", "published_display": "08 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp CFO Alex Thurman sells $1.5m in shares", "summary": "Alex R. Thurman, CFO of Glaukos Corp (NASDAQ:GKOS), sold 10,000 shares for $1.5 million at $150 per share, following an option exercise for the same number of shares at $38.68. The transactions were executed", "url": "https://www.investing.com/news/insider-trading-news/glaukos-corp-cfo-alex-thurman-sells-15m-in-shares-93CH-4782916", "source_name": "Investing.com", "published_at": "2026-07-08T09:15:00", "published_display": "08 Jul 2026 09:15", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos sets July 29 call for Q2 results after market close", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOX3I4NDlsTTFpX2VzMzZ4aVVzcmZrenNSd1JTSGNUX0tCczBzT0otRmstUl95emtuWTg5Z3RVS0dUMjE4dXM5b2xwNnlSNTlPZFFKWkFNM1JnUzJlWldoLWhTM05FU05aUXNVRzkxVlN4QUtuajZnbzMzT0VlNnAzWS1lSlpJZk9oXy1Zajhyb0MtY213clVRQVJTWko3UGFSM2F3ZEVFdDNvTWNlUFpQeUt1TWM1NGdF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Glaukos Corporation (GKOS) Affects Rotational Strategy Timing", "summary": "Quantitative analysis indicates strong sentiment for Glaukos Corporation (GKOS) across all time horizons, supporting an overweight bias. The article provides three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, a", "url": "https://news.stocktradersdaily.com/news_release/78/How_Glaukos_Corporation_GKOS_Affects_Rotational_Strategy_Timing_070726054202_1783460522.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T17:42:00", "published_display": "07 Jul 2026 17:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock and its role in eye disease treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQLUJqWjBoeVdWN0ZuWVJPUWZ2TmxxbENsY0NtNElpOWpsYTdxLThRdHRndkU1dnQ4a256eDI3U1Q2VTBQc3pCc0RtellFS050OHpobzA0N2c3ZF9NeXdDbFprZ0lFU0Fuck12VkZVTHh2cDVwbVBhZEdjcWszZDRkZS1RR3lqZkJlRkVoWjlBaUpxVXlaZnloOU8tWGZVUVlLc1E4eVUtTEU1SkFqb3pBSm9xSlVsUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T15:20:20+00:00", "published_display": "07 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares", "summary": "Glaukos Corp. (NYSE: GKOS) has filed a Form 144, indicating a proposed sale of 10,000 shares of common stock stemming from a Stock Option Exercise. The filing lists Fidelity Brokerage Services LLC as the broker/dealer and cites July 6, 2026, as the securities-to-be-sold date, wit", "url": "https://www.stocktitan.net/sec-filings/GKOS/144-glaukos-corp-sec-filing-cdfdff5bcb82.html", "source_name": "Stock Titan", "published_at": "2026-07-06T15:40:36", "published_display": "06 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos stock rating reiterated at Outperform by William Blair", "summary": "William Blair has reiterated an Outperform rating on Glaukos Corporation (NYSE:GKOS) stock, which is trading near its 52-week high and is up 31% year-to-date despite recent losses. The reiteration comes as the company navigates a proposed local coverage determination (LCD) for it", "url": "https://www.investing.com/news/analyst-ratings/glaukos-stock-rating-reiterated-at-outperform-by-william-blair-93CH-4776090", "source_name": "Investing.com", "published_at": "2026-07-06T11:43:07", "published_display": "06 Jul 2026 11:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Gains Fresh Attention As Trial Progress Keeps Its Valuation Story Alive", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GKOS Jumps As Glaukos Wins Bullish Targets And Trial Milestone", "summary": "Glaukos Corporation (GKOS) stock surged by 7.84% following promising trial results for its glaucoma treatment, Epioxa, which also led to increased price targets from Citi and Needham. Analysts maintain an average \"Buy\" rating with a mean price target of $157.50, driven by the com", "url": "https://stockstotrade.com/news/glaukoscorporation-gkos-news-2026_07_04-2/", "source_name": "StocksToTrade", "published_at": "2026-07-04T15:09:21", "published_display": "04 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Proxy filing Summary", "summary": "Glaukos (GKOS) has scheduled its Annual Meeting for May 28, 2026, where shareholders will vote on director elections, executive compensation, and auditor ratification. The company reported a 32% net sales growth in 2025, reaching $507M, with major product launches like iDose TR a", "url": "https://quartr.com/events/glaukos-gkos-proxy-filing_ofdonT36", "source_name": "Quartr", "published_at": "2026-07-03T15:39:25", "published_display": "03 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWnBMYmhNSEo0aXdhWkVBSXBVYVRzUlQ2LXhFdWtSWkZKdUVMMk50cC1Fc0dWakc4M3BQbFB1WUVtX3hkWEhjc3dkLWdzYURmcTYwd0tNNHI2TUZ5ZzBRYzZ6bW5GWTRfMDVVd254VkJ6N2tEdDExRG9RbTBucXM1U3lmWWdneHYxa3JQWUZQeDdfemxjWGZoVUxxRV9aZkxMQWd5c2lqTzB0OUZwaHJGN0Z2dFJxYlluMHZJ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-02T21:24:00+00:00", "published_display": "02 Jul 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos stock hits 52-week high at 148.12 USD", "summary": "Glaukos (GKOS) stock has reached a new 52-week high of $148.12, reflecting a 40.91% increase in value over the past year and a nearly 22% year-to-date return, despite an InvestingPro analysis suggesting it may be overvalued. The company's revenue grew 36% in Q1 2026, and it recen", "url": "https://www.investing.com/news/company-news/glaukos-stock-hits-52week-high-at-14812-usd-93CH-4774011", "source_name": "Investing.com", "published_at": "2026-07-02T20:12:21", "published_display": "02 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 GLAUKOS Corp For: 1 July By Investing.com", "summary": "This article reports on the filing of Form 144 for GLAUKOS Corp, dated July 1st. It provides various financial market data and news headlines but no further details about the Form 144 itself. The content is primarily a placeholder announcement from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-144-glaukos-corp-for-1-july-93CH-4716682", "source_name": "Investing.com Canada", "published_at": "2026-07-01T16:40:06", "published_display": "01 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GKOS (GKOS) insider sells 3,630 shares total across April and June 2026", "summary": "A recent Form 144 filing indicates that Glaukos Corp (GKOS) insider Tomas Navratil sold a total of 3,630 shares across two transactions in April and June 2026, generating over $447,000. Additionally, Navratil had 716 shares vest on March 24, 2025, from restricted stock. These dis", "url": "https://www.stocktitan.net/sec-filings/GKOS/144-glaukos-corp-sec-filing-59558174726b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T16:40:06", "published_display": "01 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares", "summary": "Glaukos Corp's Chief Development Officer, Tomas Navratil, reported a tax-related share disposition. On June 25, 2026, 483 common shares were withheld by the company at $142.57 each to cover tax obligations from vested restricted stock units. Following this, Navratil directly hold", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-5c9426d606b7.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:36", "published_display": "30 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Glaukos Corp For: 29 June By Investing.com", "summary": "This article reports on a Form 4 filing for Glaukos Corp (GKOS) dated June 29. It notes a slight downturn in Glaukos Corp's stock and provides a financial markets overview. The piece also includes various market indices, commodity prices, and trending stock data.", "url": "https://ng.investing.com/news/stock-market-news/form-4-glaukos-corp-for-29-june-93CH-2579053", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T12:39:35", "published_display": "30 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Glaukos Corporation \u2013 NYSE:GKOS", "summary": "This page from TradingView provides financial information for Glaukos Corporation (NYSE: GKOS), specifically focusing on its forward price-to-sales ratio. It indicates that the company is listed on the New York Stock Exchange and presents various financial and community-related s", "url": "https://www.tradingview.com/symbols/NYSE-GKOS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:10:08", "published_display": "30 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding", "summary": "Glaukos Corp's CEO, Thomas William Burns, reported updated holdings of the company's common stock, primarily held through various family and charitable trusts. The update also indicated a disposition of 4,059 directly held shares at $142.57 each to cover tax obligations related t", "url": "https://www.stocktitan.net/sec-filings/GKOS/form-4-glaukos-corp-insider-trading-activity-15f7c7fef90d.html", "source_name": "Stock Titan", "published_at": "2026-06-29T22:09:50", "published_display": "29 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Markets Slide this week \u2014 One Stock to Consider: Glaukos Corporation (NYSE: GKOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVmFKTTdKNEZLVzYxWTFrSzlWYm1rUmd5WUZQc3NPRkpsZTFtcU9hb295aGljNUhJZENRb3Z2WWZ2bG82elhla0pQN0VHaU1yekVQaXc0UUs2RVpIRVh5Z0lZRG95dl9hZ2VqTmJNbHhRbDBKclZfX19RWFhqbzVhRndBdGpRS1JBQ3dRMW82dENZWlZ0ZHFJWDZUUjBVMmpvZERxeU0tbDluS1FaUEE?oc=5", "source_name": "Kalkine", "published_at": "2026-06-26T12:43:00+00:00", "published_display": "26 Jun 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp Actuals & Estimates (NYSE:GKOS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOZXFudWQ5Z3dWaG45dkE0UVZBdWtJQ1JFYkNCQm9rdFlnbEVCZzVqQUZNcWx6X0x1NUhNcUhDWjhBV0w3UXVLaEFQTW5JMFZQNXRlWmctSHFxaWpqUTVLbGtFdFNSUlNYUG5zZ1J2RmdsazNGVTZ5cGo1bEJtTDJwakRuMA?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T18:17:31+00:00", "published_display": "25 Jun 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeTVUSzkyYW44cUwzNGtLbWNnX2RCS0dOd3JyVENLdC0yMWU0NndiRHhCVUVzSERtMUVzemRybEpfTWlzVUpuSWhfYlEzSnhTLV9YYlpsSFN5RUpHd0o5aVJZMG5QcFJwLUJqdGxleVhLYzhJd3FlNkJJZHN5VmE2eXRQWFc2R2dKR19GYlBaTDlrTThVd1oxYjRSa3JUWTBnZ2VwS1RTYUxjQzlOMnVoOU1tbENPLXBsYWVOV29CQlRyc1hfenJEUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPLW1sTzJKZ2dHbUVkemZiRVNERm1pdGdpSTVDLWFPdHFJbWR0Yko0eTdmUnRHUVhzV3FTUF9jTVFKZGdfZ2VxcVVTdHhTNlhMZXlXNmdhUVJBS09vXzNWMFVTNE8taEVaZ0lXUC1tN3RTNlgzMUdRUkxScXdwbm9yNDd5SlpLbVoycTdWa3o4UXF5WW5iRHBvQVhnQzM3WmRI?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQLS1Ebm1sS1BaU3F3d0FQZjJ3TnkxWXlxejluSzUwUlFrdElZUFZrNFdsU09NT3Ayc0s4ejVUOUVsS2xLMkhzZVVyaE5oMnlERHhaMGllWkRXWWFOQlc5Z1RKVXprSklwSFEwbEYxRU1KanM2dFRnamtURFl1RFVTMFRlMXYzZEFOZmJRSUJpeFcycHV2cEpYenk2MA?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) director Leana Wen granted RSUs and options in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTkFhbVo1YTVYNGxTZHh2aUF3ZW1CRnFaM1lRYXRaYjYxbFVrWVhQcFVRZlYwR0RROGd1SEJiVEhVVDh1cTdHbkcxSmpwd0pBUjFsOTh4N3cyMkxRQ0ZaeFJPUVhROVZodnp3Z0hVb0l6dE5WSko1WEVwckt3bkhaU3lhdmVfSFV3anlHcFVWSDk5NlpLV2RDcDFFUnBKNkJpUGk5REtRX1Z0QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corp stock (US3773221029): shares active on NYSE as market watches next catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOVlFfV0tKcmRncGR6QTNSOWo0cDREZXFMTGZSZG4xTmQwWWlKel9JT284c2RvdUsya194cGNQN1labUNpZjQ3c0VyWUpXWmtmUFNsYkVEdTlHd1A4cHRJTExfU0Nja2lJLXJORFQtN1FFN24yNXdBcFlkYW5sY19aWTVENG9FY1E4Q3dWVmhqZFRRcEF4V3lSSmwyZjRFdGVJZE8xUWhIWE5KN0RoeXUxR2tpaDQ1bndYZEEwcHA4TWlkMVdHbFlKYmVn?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQNlFxNmtMeGRBMEtnbHRyblhfbTJtdlpNa3NpOWhLemNfanZKdHFjN0gzRTRBOXIzb1hJVUVndGlpazNveVJMYk5jYlc4aWpXRl84bU5nT0ZCXzJlNm1SbGxPQWRyeXZOanhMTVp2N2lQQmVRUTJMTk16eEpJakJEYjRleW1RTUFjWHpuQkF0Y2xrMXlZZUxqcDJVRV9jY1BzN2J3RVE3bWt5eDRsNzJjYXJsRWN2WlFlc285TTVoZ3B0Z2p2T01Hb2pKZldmWW9yZG5BYlR0MHJ4R0ZoMkZUOFBLTjJ6S1lRWW5uQ2FYYmM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings Signal Promising Upside in the Medical Device Arena", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxORG1xRk5kREwwRERWeTZjY1ZweVFVQWVvcVdFdEVZV1YyNHJxNE5FeHBkWUhUVjlFN0VuWFYxWVp5RTkzWnl6VFBOZmQ1MXEwRVdUbnoxb2xIX3N5bjg2czhobExmY0xBRGNzMkpVR090dFgwVE80eTVxOUl0ek1ON3hyZVhMTEw0cjdlWjlUcFpUbUZWNE8xUk5PTnZVU3h0MWJTcGtUOGtTRkR0dnQ4RmVzWEdPcmVyLVFTcWtpWUVFTFVtZXE1QkYxQTBGVlZjcEswNUgzMkR0T3lxUGxmNTUxamcyTlVRbUx4NGc0aVhhMmM?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Q1 Loss Of US$0.34 EPS Reinforces Bearish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOY1Uyd0h6eTFDUC1HZ0YxSmNicDJ0d3h5SElCSW4ySlJXVkZFeEFxZHNrelFKNmpVYlA0VVhfOXZTZ281MHRobkhwZXVDcUNob1R5TlZ6UlNHMVlkdmFtTXhDMy1JSTFFM1NQRVlWeVVlbkdyZFFRU2JBaWJmLTRHUXIxd0ZiTTY1Q2xzaVhOakhTSFpLZFg3Q3BnMVVsVnE4?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Rule 144: Fidelity lists 10,000\u2011share resale, insider trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNMm9naDFTcG9fWEhuYjVlQmZzQUhxd2NCaENRM2xPMUs2c3VEUzJHNHV4bGRuSUZBakM1bDJxVldQYzlOYmFVM2loeFEwbDZDdzNpd1ZwS1Z4QzZpaW9oREZQZ2N5SHQwekF3NHdRaS0wYTdxaWRBRWh4NWc1NUZWOVQ3aWRGNXR2RlcwNy1QZDJ6Mjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNQ21JZjRqRGlnTFAtM1pMSFdRWkM4RzE0Q1MtdzhEbjNvSEQ0angzYlJYWnUyUEQ4U1FkN2VRaXhYSEwtLUdOSDBtczNPUlVyR1hQNHR2VHMtYlF5UnBzdHUwZnVLSnBoTGN0MnpkekVEWjB3S3kxNmV6eGRQR2QzaXh4dG1BU2w0aDNoYTk1R1dlZ0tSa3JDcnA1d0c?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 65, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 46, "score": 55, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.35, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 9.49, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 152.72, "latest_week": "2026-07-10", "one_week_move": 3.0, "four_week_move": 20.4, "twelve_week_move": 22.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.887591, "market_dynamics_buy_signal": false, "relative_strength": 27.671381, "fair_value_gap": 44.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.7166, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.0% over one week, +20.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 10}, {"label": "Investing.com", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Ad Hoc News", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.0% over one week, +20.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating"}], "updated_at": "2026-07-16T14:31:02.214371+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}